M&A / Deals Angelini inks $4.1B Catalyst buy to enter US rare disease market BioSpaceCatalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.Rare DiseaseRead full story pharminent May 7, 2026 (Last updated: May 7, 2026) BioSpace Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings. Rare Disease Read full story Post navigation Previous: Bayer plans filings for cardiac amyloidosis imaging agentNext: Novo’s CEO champions “record-breaking start” for Wegovy pill in US market Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026